[8-K] IMMUNIC, INC. Reports Material Event

Rhea-AI Filing Summary

Immunic, Inc. announced presentations of vidofludimus calcium data at the 41st ECTRIMS congress in Barcelona, held September 24-26, 2025. The company issued a press release dated September 25, 2025, and posted a corporate presentation on its website on September 24, 2025, which includes new data from the Phase 2 CALLIPER trial in progressive multiple sclerosis. The filing lists the press release and the presentation as exhibits and states the report was signed by CEO Daniel Vitt.

Positive

• Public dissemination of Phase 2 CALLIPER data via presentations at a major scientific congress (ECTRIMS).
• Corporate presentation posted on the company website, providing investors and clinicians access to the new data.

Negative

• Filing does not include the actual Phase 2 CALLIPER results, endpoints, or numerical data, limiting assessment of clinical impact.
• No financial or regulatory details

Insights

Financial Analyst

TL;DR: Company disclosed presentations and posted Phase 2 CALLIPER data but the filing does not include trial results or financial metrics.

The 8-K notifies investors that Immunic presented vidofludimus calcium data at a major MS conference and posted a corporate presentation online. The disclosure confirms public dissemination of clinical information, which can affect investor perception, but the filing itself does not provide efficacy, safety, enrollment, or statistical outcomes from the Phase 2 CALLIPER trial. Without numeric results or guidance, materiality to valuation is indeterminate from this document alone.

Industry Specialist (Neurology/Clinical Development)

TL;DR: Clinical data were presented publicly at ECTRIMS and posted online; the filing does not report the actual data content or conclusions.

The company’s action—oral and poster presentations at ECTRIMS and posting of a presentation—indicates formal dissemination of Phase 2 CALLIPER findings to the medical community. However, the 8-K does not include slides, data points, endpoints, or safety results within the filing text. As a result, the scientific or regulatory implications cannot be assessed from this filing alone; interested parties must review the posted presentation or press release for specific trial outcomes.

false 0001280776 0001280776 2025-09-25 2025-09-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2025

IMMUNIC, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36201	56-2358443
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1200 Avenue of the Americas, Suite 200

New York, NY 10036

USA

(Address of principal executive offices)

Registrant’s telephone number, including area code: (332) 255-9818 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, par value $0.0001	IMUX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01. Other Events.

On September 25, 2025, Immunic, Inc. (the “Company” or “Immunic”) issued a press release (the “Press Release”) announcing the presentation of key vidofludimus calcium data in an oral and four poster presentations (collectively, the “Presentation”), at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025 in Barcelona, Spain. On September 24, 2025, Immunic posted a corporate presentation on the Company's website including new data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis.

The Press Release and Presentation are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

The information in Item 8.01 of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this Current Report on Form 8-K, the Press Release and the Presentation are “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current Report on Form 8-K, the Presentation, and the Press Release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on March 31, 2025, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this Current Report on Form 8-K, the Press Release, or the Presentation speaks only as of the date of the Current Report on Form 8-K, the Press Release or the Presentation, respectively. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this Current Report on Form 8-K, the Press Release and the Presentation.

Item 9.01. Financial Statements and Exhibits.

Exhibit	Description
99.1	Press Release, dated September 25, 2025.
99.2	Presentation, dated September 24, 2025.
104	Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: September 25, 2025	Immunic, Inc.
	By:	/s/ Daniel Vitt
		Daniel Vitt
		Chief Executive Officer

FAQ

What did Immunic (IMUX) disclose in this 8-K?

The company disclosed it presented vidofludimus calcium data at the 41st ECTRIMS congress and posted a corporate presentation with new Phase 2 CALLIPER trial data on its website.

Does the 8-K include the Phase 2 CALLIPER trial results?

No. The filing references the press release and presentation but does not include trial results, endpoints, or numeric data within the 8-K text.

Where can investors find the new data referenced in the filing?

The 8-K states the company posted a corporate presentation on its website dated September 24, 2025, and issued a press release dated September 25, 2025.

Were any exhibits included with the 8-K?

Yes. The filing lists Exhibit 99.1 (Press Release dated September 25, 2025), Exhibit 99.2 (Presentation dated September 24, 2025), and Exhibit 104 (Inline XBRL cover page file).

Who signed the 8-K for Immunic?

The filing was signed by Daniel Vitt, Chief Executive Officer.